Navigation Links
Injection Reverses Heart-Attack Damage
Date:7/23/2009

/p>

When the researchers also stimulated production of a cellular receptor for NRG1, known as ErbB4, cardiomyocyte proliferation was further enhanced, demonstrating that NRG1 works by stimulating this receptor. They also identified the specific kinds of cardiomyocytes (mononucleated) that are most likely to respond to treatment.

In 2007, Kuhn and colleagues first demonstrated that the heart has dormant regenerative capacities that can be reawakened. Kuhn developed a sponge-like patch, soaked in a compound called periostin that is abundant in the developing fetal heart (and in injured skeletal muscle) but scarce in adult hearts. When the patch was placed over the site of cardiac injury in rats, it induced cardiomyocyte proliferation and improved heart function (Nature Medicine 2007; 13:962-9). Similar results were seen in larger animals, and periostin is now in preclinical development at Children's Hospital Boston for future application in human patients with heart failure.

The new work adds a second compound to the heart-regeneration toolbox, and reveals how both periostin and NRG1 work at the cellular and molecular level, an essential step in predicting possible side effects. Both compounds ultimately act on the same cellular pathway, Kuhn found.

"We applied periostin locally at the site of cardiac injury, but NRG1 works when given by systemic injection - a very promising result that suggests it may be feasible to use this in the clinic to treat heart failure," says Kuhn, who won a first prize Young Investigator Award, from the American College of Cardiology in 2007.

The study was funded by the Department of Cardiology at Children's Hospital Boston, the Charles Hood Foundation, and the American Heart Association.

Children's Hospital Boston is home to the world's largest research enterprise
'/>"/>

SOURCE Children's Hospital of Boston
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014   Fruit Street Health (Fruit Street), ... round of funding. The round, which ... series of individual investors, the majority of whom are ... initial round are; Houston Cardiology Consultants Partner Asif ... Childs, Rapha Family Medicine Practice Owner Frances Ilozue ...
(Date:9/18/2014)... N.J. , Sept. 18, 2014  ADM ... Gianluca DeNovi , Ph.D. to its corporate Advisory ... is an instructor at the Harvard Medical School ... of Rome.  He received his Masters degree in ... Control Systems from the University of Bologna. After spending ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
(Date:9/18/2014)... don,t worry, it,s a good thing! As scientists have ... bad. Many active enzymes and bacteria are merely benign, ... important part of our digestive system or can help ... an opportunistic yeast pathogen and model organism for research, ... ecosystem. However, when our immune system is stressed on ...
(Date:9/18/2014)... Non-governmental stakeholders will convene a one-day conference at ... George Washington University on September 25, 2014 to discuss ... towards GHSA implementation. The purpose of this event is ... over the next five years, including action plans to ... 2014 launch of the GHSA, international organizations and more ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of ... from a four-year, $1.3 million grant to the Los ... the research and development of a vaccine to protect ... Methicillin-resistant Staphylococcus aureus (MRSA). , The ... the NIH awarded the grant to LA BioMed infectious ...
(Date:9/18/2014)... DURHAM, N.C. Dangerous new pathogens such as the ... even ancient scourges such as the bubonic plague are ... body responds to infections. , In a study published ... , researchers at Duke Medicine and Duke-NUS Graduate Medical ... cause bubonic plague hitchhike on immune cells in the ...
(Date:9/18/2014)... ChopChop founder Sally Sampson is challenging former ... Massachusetts’s winner of the First Lady’s Healthy Lunchtime Challenge, to ... Eastern bean dip. Watch as Bill and Yonah cook side-by-side ... own healthy dips at home. The cooking demonstration will take ... Talk About Food Festival in Copley Square on September ...
Breaking Medicine News(10 mins):Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3
... surveillance, planning and interagency coordinationWASHINGTON, May 8 Environmental ... the Natural Resources Defense Council (NRDC) praised legislation introduced ... climate change. The bill is sponsored by the ... Commerce Committee,s Subcommittee on Health , U.S. Rep. ...
... This Sunday, individuals all over the nation ... women who gave them life: their mothers. While people in ... International Breast Milk Project (IBMP) hopes to inspire some to ... that helps mothers in the United States send their breast ...
... Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and ... $10.6 billion for the quarter ended March 31, 2009, ... year. Operating income in the first quarter was ... of 2008. Declines in the financial markets impacted ...
... May 8 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a definitive, 5-year distribution agreement with ... in Barcarena, Portugal, expanding on and replacing a previous ...
... - Majority have not changed their behavior or lifestyle ... May 8 A new national study among 1,477 ... become less concerned about the impact that the H1N1 ... http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO )Results ...
... Family, Inc. (Nasdaq: AFAM ), a leading regional ... Yarmuth, President and Chief Executive Officer, and Steve Guenthner, Senior ... at two upcoming investor conferences. The first presentation will ... Stock Conference at the Four Seasons Hotel in Chicago, IL., ...
Cached Medicine News:Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 2Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 3Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 4Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 3Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 2Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 2Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 4Health News:Almost Family to Present at Two Upcoming Conferences 2
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: